Point72 Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Point72 Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-647,008	Closed	-$1.1M	–	1375
2022 Q2	$1.1M	Buy	647,008 +64,500	+11%	+$111K	﹤0.01%	1051
2022 Q1	$1.2M	Buy	582,508 +17,300	+3%	+$46.7K	﹤0.01%	936
2021 Q4	$2.12M	Buy	565,208 +488,908	+641%	+$2.23M	0.01%	818
2021 Q3	$394K	Sell	76,300 -1,982,792	-96%	-$8.89M	﹤0.01%	940
2021 Q2	$8.77M	Buy	2,059,092 +80,858	+4%	+$392K	0.04%	489
2021 Q1	$10.5M	Buy	1,978,234 +228,234	+13%	+$1.31M	0.05%	413
2020 Q4	$9.43M	Buy	+1,750,000	New	+$9.51M	0.05%	448
2018 Q4	–	Sell	-300,000	Closed	-$4.07M	–	928
2018 Q3	$4.07M	Buy	+300,000	New	+$3.14M	0.02%	648
2018 Q1	–	Sell	-96,900	Closed	-$647K	–	912
2017 Q4	$647K	Buy	+96,900	New	+$748K	﹤0.01%	829
2017 Q3	–	Sell	-545,500	Closed	-$2.45M	–	853
2017 Q2	$2.45M	Buy	545,500 +22,200	+4%	+$116K	0.01%	618
2017 Q1	$2.88M	Buy	+523,300	New	+$2.29M	0.02%	622
2016 Q1	–	Sell	-130,200	Closed	-$1.57M	–	710
2015 Q4	$1.57M	Buy	+130,200	New	+$1.28M	0.01%	573

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management's ADAP Position: Q3 2022 in Review

Point72 Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2022, closing a stake of 647,008 shares — an estimated $1.1M sold.

Point72 Asset Management first reported a position in ADAP in Q4 2015 and held it in 12 quarters. The position peaked at $10.5M in Q1 2021. 68 funds tracked by Wall St. Rank hold ADAP as of Q3 2022.

Point72 Asset Management reported no remaining Adaptimmune Therapeutics position as of Q3 2022 after selling out during the quarter.
Point72 Asset Management sold 647,008 Adaptimmune Therapeutics shares in Q3 2022, an estimated $1.1M.
Point72 Asset Management first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 12 quarters.
Point72 Asset Management's Adaptimmune Therapeutics position peaked at $10.5M in Q1 2021.
68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2022.

Based on Point72 Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.